Akopov S, Sercombe R, Seylaz J
Laboratoire de Recherches Cerebrovasculaires, Universite Paris VII, France.
Cerebrovasc Brain Metab Rev. 1996 Spring;8(1):11-94.
In the last two decades, a tremendous amount of knowledge has been accumulated in various fields of biomedical research that discloses mechanisms of platelet/leukocyte/endothelium interactions. Occupying a strategically important location between circulating blood and underlying tissues, the endothelium effectively modulates both the functional state of the blood cells and the tone of vascular smooth muscle by generating or metabolizing a host of humoral substances. Under normal conditions, the endothelium releases agents with predominantly vasodilator and antiaggregant/anticoagulant activity that prevent thrombotic and angiospastic disorders. However, a variety of pathophysiological stimuli may trigger endothelial reorganization with the expression of different prothrombotic factors and activation of platelets and leukocytes that, combined, leads to blood cell adhesion to the endothelial monolayer, aggregation as thrombi, and the formation of numerous spasmogenic substances. Activation of the blood cells in the vicinity of the endothelium may induce endothelial dysfunction/injury, resulting in impairment of normal endothelial antispasmodic control. Within the microcirculatory bed, intravascular activation of the blood cells leads to scattered microvessel plugging, increased vascular permeability, edema formation, and cytotoxic actions of blood cell-released agents on the underlying tissue. A growing body of evidence suggests that these processes may be involved in pathophysiological cerebrovascular reactions including symptomatic angiospasm following subarachnoid hemorrhage, segmental occlusive constriction in atherosclerotic cerebral arteries, and constrictive vasomotion in microvessels. A perturbation in the delicate equilibrium between blood cells and endothelium in the microcirculation seems to be a factor aggravating ischemic brain damage or even primarily causing focal cerebral ischemia and scattered microinfarctions. Increased predisposition to these pathophysiologic events might influence unfavorably the effects of risk factors such as hypercholesterolemia, hypertension, and diabetes on cerebrovascular morbidity and mortality. Although the importance of blood cell/endothelium imbalance appears to be clear, its pharmacologic regulation is not sufficiently established. Some drugs have been demonstrated to limit platelet and/or leukocyte activity and protect the endothelial defense mechanisms, but the optimal therapeutic strategy has yet to be elaborated.
在过去二十年中,生物医学研究的各个领域积累了大量知识,揭示了血小板/白细胞/内皮细胞相互作用的机制。内皮细胞位于循环血液与下层组织之间的战略重要位置,通过产生或代谢多种体液物质,有效地调节血细胞的功能状态和血管平滑肌的张力。在正常情况下,内皮细胞释放的物质主要具有血管舒张和抗聚集/抗凝活性,可预防血栓形成和血管痉挛性疾病。然而,多种病理生理刺激可能引发内皮细胞重组,导致不同促血栓形成因子的表达以及血小板和白细胞的激活,这些因素共同作用会导致血细胞黏附于内皮单层,聚集形成血栓,并产生大量致痉挛物质。内皮细胞附近血细胞的激活可能诱导内皮功能障碍/损伤,导致正常内皮抗痉挛控制受损。在微循环床内,血细胞的血管内激活会导致微血管散在性阻塞、血管通透性增加、水肿形成以及血细胞释放的物质对下层组织的细胞毒性作用。越来越多的证据表明,这些过程可能参与了病理生理脑血管反应,包括蛛网膜下腔出血后的症状性血管痉挛、动脉粥样硬化性脑动脉的节段性闭塞性狭窄以及微血管的收缩性血管运动。微循环中血细胞与内皮细胞之间微妙平衡的扰动似乎是加重缺血性脑损伤甚至主要导致局灶性脑缺血和散在性微梗死的一个因素。对这些病理生理事件易感性的增加可能会对高胆固醇血症、高血压和糖尿病等危险因素对脑血管发病率和死亡率的影响产生不利影响。尽管血细胞/内皮细胞失衡的重要性似乎很明显,但其药物调节尚未充分确立。一些药物已被证明可限制血小板和/或白细胞活性,并保护内皮防御机制,但最佳治疗策略仍有待完善。